抗冠状病毒疫苗：过去对SARS-CoV-1和MERS-CoV的调查，BioNTech/辉瑞，Moderna，Oxford/AstraZeneca和其他正在开发的针对SARSCoV-2感染的已批准的疫苗

V’kovski, P.; Kratzel, A.; Steiner, S.; Stalder, H.; Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol., 2021, 9(3), 155-17.
[http://dx.doi.org/10.1038/s41579-020-00468-6] [PMID: 33116300]

Chu, D.K.W.; Leung, C.Y.H.; Gilbert, M.; Joyner, P.H.; Ng, E.M.; Tse, T.M.; Guan, Y.; Peiris, J.S.M.; Poon, L.L.M. Avian coronavirus in wild aquatic birds. J. Virol., 2011, 85(23), 12815-12820.
[http://dx.doi.org/10.1128/JVI.05838-11] [PMID: 21957308]

Poon, L.L.M.; Chu, D.K.W.; Chan, K.H.; Wong, O.K.; Ellis, T.M.; Leung, Y.H.C.; Lau, S.K.P.; Woo, P.C.Y.; Suen, K.Y.; Yuen, K.Y.; Guan, Y.; Peiris, J.S.M. Identification of a novel coronavirus in bats. J. Virol., 2005, 79(4), 2001-2009.
[http://dx.doi.org/10.1128/JVI.79.4.2001-2009.2005] [PMID: 15681402]

Wang, L-F.; Anderson, D.E. Viruses in bats and potential spillover to animals and humans. Curr. Opin. Virol., 2019, 34, 79-89.
[http://dx.doi.org/10.1016/j.coviro.2018.12.007] [PMID: 30665189]

Memish, Z.A.; Mishra, N.; Olival, K.J.; Fagbo, S.F.; Kapoor, V.; Epstein, J.H.; Alhakeem, R.; Durosinloun, A.; Al Asmari, M.; Islam, A.; Kapoor, A.; Briese, T.; Daszak, P.; Al Rabeeah, A.A.; Lipkin, W.I. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg. Infect. Dis., 2013, 19(11), 1819-1823.
[http://dx.doi.org/10.3201/eid1911.131172] [PMID: 24206838]

Hofmann, H.; Pyrc, K.; van der Hoek, L.; Geier, M.; Berkhout, B.; Pöhlmann, S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. USA, 2005, 102(22), 7988-7993.
[http://dx.doi.org/10.1073/pnas.0409465102] [PMID: 15897467]

Xiong, H.; Ye, X.; Li, Y.; Wang, L.; Zhang, J.; Fang, X.; Kong, J. Rapid differential diagnosis of seven human respiratory coronaviruses based on centrifugal microfluidic nucleic acid assay. Anal. Chem., 2020, 92(21), 14297-14302.
[http://dx.doi.org/10.1021/acs.analchem.0c03364] [PMID: 33073982]

Gossner, C.; Danielson, N.; Gervelmeyer, A.; Berthe, F.; Faye, B.; Kaasik Aaslav, K.; Adlhoch, C.; Zeller, H.; Penttinen, P.; Coulombier, D. Human-dromedary camel interactions and the risk of acquiring zoonotic middle east respiratory syndrome coronavirus infection. Zoonoses Public Health, 2016, 63(1), 1-9.
[http://dx.doi.org/10.1111/zph.12171] [PMID: 25545147]

Sheahan, T.; Rockx, B.; Donaldson, E.; Sims, A.; Pickles, R.; Corti, D.; Baric, R. Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium. J. Virol., 2008, 82(5), 2274-2285.
[http://dx.doi.org/10.1128/JVI.02041-07] [PMID: 18094188]

Sheahan, T.; Rockx, B.; Donaldson, E.; Corti, D.; Baric, R. Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus. J. Virol., 2008, 82(17), 8721-8732.
[http://dx.doi.org/10.1128/JVI.00818-08] [PMID: 18579604]

Gaunt, E.R.; Hardie, A.; Claas, E.C.J.; Simmonds, P.; Templeton, K.E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J. Clin. Microbiol., 2010, 48(8), 2940-2947.
[http://dx.doi.org/10.1128/JCM.00636-10] [PMID: 20554810]

Woldemeskel, B.A.; Kwaa, A.K.; Garliss, C.C.; Laeyendecker, O.; Ray, S.C.; Blankson, J.N. Healthy donor T cell responses to common cold coronaviruses and SARS-CoV- 2. J. Clin. Invest., 2020, 130(12), 6631-6638.
[http://dx.doi.org/10.1172/JCI143120] [PMID: 32966269]

Pene, F.; Merlat, A.; Vabret, A.; Rozenberg, F.; Buzyn, A.; Dreyfus, F.; Cariou, A.; Freymuth, F.; Lebon, P. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infect. Dis., 2003, 37(7), 929-932.
[http://dx.doi.org/10.1086/377612] [PMID: 13130404]

Jordan, P.C.; Stevens, S.K.; Deval, J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir. Chem. Chemother., 2018, 26, 2040206618764483.,
[http://dx.doi.org/10.1177/2040206618764483] [PMID: 29562753]

Abdul-Rasool, S.; Fielding, B.C. Understanding Human Coronavirus HCoV-NL63~!2009-11-13~!2010-04-09~ !2010-05-25~! Open Virol. J., 2010, 4(1), 76-84.
[http://dx.doi.org/10.2174/1874357901004010076] [PMID: 20700397]

Esper, F.; Weibel, C.; Ferguson, D.; Landry, M.L.; Kahn, J.S. Coronavirus HKU1 infection in the United States. Emerg. Infect. Dis., 2006, 12(5), 775-779.
[http://dx.doi.org/10.3201/eid1205.051316] [PMID: 16704837]

Cevik, M.; Tate, M.; Lloyd, O.; Maraolo, A.E.; Schafers, J.; Ho, A. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: A systematic review and meta-analysis. Lancet Microbe., 2021, 2(1), e13-e22.,
[http://dx.doi.org/10.1016/S2666-5247(20)30172-5] [PMID: 33521734]

Andersen, K.G.; Rambaut, A.; Lipkin, W.I.; Holmes, E.C.; Garry, R.F. The proximal origin of SARS-CoV-2. Nat. Med., 2020, 26(4), 450-452.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]

Rabaan, A.A.; Al-Ahmed, S.H.; Haque, S.; Sah, R.; Tiwari, R.; Malik, Y.S.; Dhama, K.; Yatoo, M.I.; Bonilla-Aldana, D.K.; Rodriguez-Morales, A.J. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez. Med., 2020, 28(2), 174-184.
[PMID: 32275259]

Peeri, N.C.; Shrestha, N.; Rahman, M.S.; Zaki, R.; Tan, Z.; Bibi, S.; Baghbanzadeh, M.; Aghamohammadi, N.; Zhang, W.; Haque, U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned? Int. J. Epidemiol., 2020, 49(3), 717-726.
[http://dx.doi.org/10.1093/ije/dyaa033] [PMID: 32086938]

Gordon, D.E.; Hiatt, J.; Bouhaddou, M.; Rezelj, V.V.; Ulferts, S.; Braberg, H.; Jureka, A.S.; Obernier, K.; Guo, J.Z.; Batra, J.; Kaake, R.M.; Weckstein, A.R.; Owens, T.W.; Gupta, M.; Pourmal, S.; Titus, E.W.; Cakir, M.; Soucheray, M.; McGregor, M.; Cakir, Z.; Jang, G.; O’Meara, M.J.; Tummino, T.A.; Zhang, Z.; Foussard, H.; Rojc, A.; Zhou, Y.; Kuchenov, D.; Hüttenhain, R.; Xu, J.; Eckhardt, M.; Swaney, D.L.; Fabius, J.M.; Ummadi, M.; Tutuncuoglu, B.; Rathore, U.; Modak, M.; Haas, P.; Haas, K.M.; Naing, Z.Z.C.; Pulido, E.H.; Shi, Y.; Barrio-Hernandez, I.; Memon, D.; Petsalaki, E.; Dunham, A.; Marrero, M.C.; Burke, D.; Koh, C.; Vallet, T.; Silvas, J.A.; Azumaya, C.M.; Billesbølle, C.; Brilot, A.F.; Campbell, M.G.; Diallo, A.; Dickinson, M.S.; Diwanji, D.; Herrera, N.; Hoppe, N.; Kratochvil, H.T.; Liu, Y.; Merz, G.E.; Moritz, M.; Nguyen, H.C.; Nowotny, C.; Puchades, C.; Rizo, A.N.; Schulze-Gahmen, U.; Smith, A.M.; Sun, M.; Young, I.D.; Zhao, J.; Asarnow, D.; Biel, J.; Bowen, A.; Braxton, J.R.; Chen, J.; Chio, C.M.; Chio, U.S.; Deshpande, I.; Doan, L.; Faust, B.; Flores, S.; Jin, M.; Kim, K.; Lam, V.L.; Li, F.; Li, J.; Li, Y-L.; Li, Y.; Liu, X.; Lo, M.; Lopez, K.E.; Melo, A.A.; Moss, F.R., III; Nguyen, P.; Paulino, J.; Pawar, K.I.; Peters, J.K.; Pospiech, T.H., Jr; Safari, M.; Sangwan, S.; Schaefer, K.; Thomas, P.V.; Thwin, A.C.; Trenker, R.; Tse, E.; Tsui, T.K.M.; Wang, F.; Whitis, N.; Yu, Z.; Zhang, K.; Zhang, Y.; Zhou, F.; Saltzberg, D.; Hodder, A.J.; Shun-Shion, A.S.; Williams, D.M.; White, K.M.; Rosales, R.; Kehrer, T.; Miorin, L.; Moreno, E.; Patel, A.H.; Rihn, S.; Khalid, M.M.; Vallejo-Gracia, A.; Fozouni, P.; Simoneau, C.R.; Roth, T.L.; Wu, D.; Karim, M.A.; Ghoussaini, M.; Dunham, I.; Berardi, F.; Weigang, S.; Chazal, M.; Park, J.; Logue, J.; McGrath, M.; Weston, S.; Haupt, R.; Hastie, C.J.; Elliott, M.; Brown, F.; Burness, K.A.; Reid, E.; Dorward, M.; Johnson, C.; Wilkinson, S.G.; Geyer, A.; Giesel, D.M.; Baillie, C.; Raggett, S.; Leech, H.; Toth, R.; Goodman, N.; Keough, K.C.; Lind, A.L.; Klesh, R.J.; Hemphill, K.R.; Carlson-Stevermer, J.; Oki, J.; Holden, K.; Maures, T.; Pollard, K.S.; Sali, A.; Agard, D.A.; Cheng, Y.; Fraser, J.S.; Frost, A.; Jura, N.; Kortemme, T.; Manglik, A.; Southworth, D.R.; Stroud, R.M.; Alessi, D.R.; Davies, P.; Frieman, M.B.; Ideker, T.; Abate, C.; Jouvenet, N.; Kochs, G.; Shoichet, B.; Ott, M.; Palmarini, M.; Shokat, K.M.; García-Sastre, A.; Rassen, J.A.; Grosse, R.; Rosenberg, O.S.; Verba, K.A.; Basler, C.F.; Vignuzzi, M.; Peden, A.A.; Beltrao, P.; Krogan, N.J. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370(6521), eabe9403.
[http://dx.doi.org/10.1126/science.abe9403] [PMID: 33060197]

Heurich, A.; Hofmann-Winkler, H.; Gierer, S.; Liepold, T.; Jahn, O.; Pöhlmann, S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol., 2014, 88(2), 1293-1307.
[http://dx.doi.org/10.1128/JVI.02202-13] [PMID: 24227843]

Belouzard, S.; Millet, J.K.; Licitra, B.N.; Whittaker, G.R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 2012, 4(6), 1011-1033.
[http://dx.doi.org/10.3390/v4061011] [PMID: 22816037]

Hulswit, R.J.G.; de Haan, C.A.M.; Bosch, B.J. Coronavirus spike protein and tropism changes., 2016, 96, 29-57.

Kirchdoerfer, R.N.; Cottrell, C.A.; Wang, N.; Pallesen, J.; Yassine, H.M.; Turner, H.L.; Corbett, K.S.; Graham, B.S.; McLellan, J.S.; Ward, A.B. Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531(7592), 118-121.
[http://dx.doi.org/10.1038/nature17200] [PMID: 26935699]

Pillay, T.S. Gene of the month: the 2019-nCoV/SARS- CoV-2 novel coronavirus spike protein. J. Clin. Pathol., 2020, 73(7), 366-369.
[http://dx.doi.org/10.1136/jclinpath-2020-206658] [PMID: 32376714]

Xia, S.; Liu, M.; Wang, C.; Xu, W.; Lan, Q.; Feng, S.; Qi, F.; Bao, L.; Du, L.; Liu, S.; Qin, C.; Sun, F.; Shi, Z.; Zhu, Y.; Jiang, S.; Lu, L. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res., 2020, 30(4), 343-355.
[http://dx.doi.org/10.1038/s41422-020-0305-x] [PMID: 32231345]

Kim, C-H. SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor o-acetyl sialylation in virus-host interaction. Int. J. Mol. Sci., 2020, 21(12), 4549.
[http://dx.doi.org/10.3390/ijms21124549] [PMID: 32604730]

Artese, A.; Svicher, V.; Costa, G.; Salpini, R.; Di Maio, V.C.; Alkhatib, M.; Ambrosio, F.A.; Santoro, M.M.; Assaraf, Y.G.; Alcaro, S.; Ceccherini-Silberstein, F. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist. Updat., 2020, 53, 100721.
[http://dx.doi.org/10.1016/j.drup.2020.100721] [PMID: 33132205]

Schoeman, D.; Fielding, B.C. Coronavirus envelope protein: current knowledge. Virol. J., 2019, 16(1), 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]

Chen, B.; Tian, E-K.; He, B.; Tian, L.; Han, R.; Wang, S.; Xiang, Q.; Zhang, S.; El Arnaout, T.; Cheng, W. Overview of lethal human coronaviruses. Signal Transduct. Target. Ther., 2020, 5(1), 89.
[http://dx.doi.org/10.1038/s41392-020-0190-2] [PMID: 32533062]

Cucinotta, D.; Vanelli, M.; Declares, W.H.O. COVID-19 a Pandemic. Acta Biomed., 2020, 91(1), 157-160.
[PMID: 32191675]

Mercatelli, D.; Holding, A.N.; Giorgi, F.M. Web tools to fight pandemics: The COVID-19 experience. Brief. Bioinform., 2021, 22(2), 690-70.
[PMID: 33057582]

Arthi, V.; Parman, J. Disease, downturns, and wellbeing: Economic history and the long-run impacts of COVID-19. Explor. Econ. Hist., 2021, 79, 101381.
[http://dx.doi.org/10.1016/j.eeh.2020.101381] [PMID: 33162564]

Roviello, V.; Roviello, G.N. Lower COVID-19 mortality in Italian forested areas suggests immunoprotection by Mediterranean plants. Environ. Chem. Lett., 2020, 1-12.
[PMID: 32837486]

Ibn-Mohammed, T.; Mustapha, K.B.; Godsell, J.; Adamu, Z.; Babatunde, K.A.; Akintade, D.D.; Acquaye, A.; Fujii, H.; Ndiaye, M.M.; Yamoah, F.A.; Koh, S.C.L. A critical analysis of the impacts of COVID-19 on the global economy and ecosystems and opportunities for circular economy strategies. Resour. Conserv. Recycling, 2021, 164, 105169.
[http://dx.doi.org/10.1016/j.resconrec.2020.105169] [PMID: 32982059]

Caterino, M.; Gelzo, M.; Sol, S.; Fedele, R.; Annunziata, A.; Calabrese, C.; Fiorentino, G.; D’Abbraccio, M.; Dell’Isola, C.; Fusco, F.M.; Parrella, R.; Fabbrocini, G.; Gentile, I.; Andolfo, I.; Capasso, M.; Costanzo, M.; Daniele, A.; Marchese, E.; Polito, R.; Russo, R.; Missero, C.; Ruoppolo, M.; Castaldo, G. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Sci. Rep., 2021, 11(1), 2941.
[http://dx.doi.org/10.1038/s41598-021-82426-7] [PMID: 33536486]

Sturley, S.L.; Rajakumar, T.; Hammond, N.; Higaki, K.; Marka, Z.; Marka, S.; Munkacsi, A.B. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity. J. Lipid Res., 2020, 61(7), 972-982.
[http://dx.doi.org/10.1194/jlr.R120000851] [PMID: 32457038]

Abu-Farha, M.; Thanaraj, T.A.; Qaddoumi, M.G.; Hashem, A.; Abubaker, J.; Al-Mulla, F. The role of lipid metabolism in COVID-19 virus infection and as a drug target. Int. J. Mol. Sci., 2020, 21(10), 3544.
[http://dx.doi.org/10.3390/ijms21103544] [PMID: 32429572]

Costanzo, M.; De Giglio, M.A.R.; Roviello, G.N. SARS- CoV-2: Recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr. Med. Chem., 2020, 27(27), 4536-4541.
[http://dx.doi.org/10.2174/0929867327666200416131117] [PMID: 32297571]

Singh, T.U.; Parida, S.; Lingaraju, M.C.; Kesavan, M.; Kumar, D.; Singh, R.K. Drug repurposing approach to fight COVID-19. Pharmacol. Rep., 2020, 72(6), 1479-1508.
[http://dx.doi.org/10.1007/s43440-020-00155-6] [PMID: 32889701]

Borbone, N.; Piccialli, G.; Roviello, G.N.; Oliviero, G. Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses. Molecules, 2021, 26(4), 986.
[http://dx.doi.org/10.3390/molecules26040986] [PMID: 33668428]

Vicidomini, C.; Roviello, V.; Roviello, G.N. molecular basis of the therapeutical potential of clove (syzygium aromaticum L.) and clues to its anti-COVID-19 utility. Molecules, 2021, 26(7), 1880.
[http://dx.doi.org/10.3390/molecules26071880] [PMID: 33810416]

Roviello, V.; Musumeci, D.; Mokhir, A.; Roviello, G.N. Evidence of protein binding by a nucleopeptide based on a thymine-decorated L-diaminopropanoic acid through CD and in silico studies. Curr. Med. Chem., 2021, 28(24), 5004-5015.
[http://dx.doi.org/10.2174/0929867328666210201152326] [PMID: 33593247]

Hung, L.S. The SARS epidemic in Hong Kong: what lessons have we learned? J. R. Soc. Med., 2003, 96(8), 374-378.
[http://dx.doi.org/10.1177/014107680309600803] [PMID: 12893851]

Outbreak of severe acute respiratory syndrome-worldwide, 2003. MMWR Morb. Mortal. Wkly. Rep., 2003, 52(11), 226-228.
[PMID: 12665115]

Abdel-Moneim, A.S. Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations. Arch. Virol., 2014, 159(7), 1575-1584.
[http://dx.doi.org/10.1007/s00705-014-1995-5] [PMID: 24515532]

Oboho, I.K.; Tomczyk, S.M.; Al-Asmari, A.M.; Banjar, A.A.; Al-Mugti, H.; Aloraini, M.S.; Alkhaldi, K.Z.; Almohammadi, E.L.; Alraddadi, B.M.; Gerber, S.I.; Swerdlow, D.L.; Watson, J.T.; Madani, T.A. 2014 MERS-CoV outbreak in Jeddah-a link to health care facilities. N. Engl. J. Med., 2015, 372(9), 846-854.
[http://dx.doi.org/10.1056/NEJMoa1408636] [PMID: 25714162]

Yi, Y.; Lagniton, P.N.P.; Ye, S.; Li, E.; Xu, R-H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int. J. Biol. Sci., 2020, 16(10), 1753-1766.
[http://dx.doi.org/10.7150/ijbs.45134] [PMID: 32226295]

Sallard, E.; Halloy, J.; Casane, D.; Decroly, E.; van Helden, J. Tracing the origins of SARS-COV-2 in coronavirus phylogenies. arXiv preprint, 2020.

Gaye, B.; Fanidi, A.; Jouven, X. Denominator matters in estimating COVID-19 mortality rates. Eur. Heart J., 2020, 41(37), 3500-3500.
[http://dx.doi.org/10.1093/eurheartj/ehaa282] [PMID: 32255475]

Lvov, D.K.; Alkhovsky, S.V. Source of the COVID-19 pandemic: Ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus). Prob. of Vir., Rus. jrn., 2020, 65(2), 62-70.

Hatmal, M.M.; Alshaer, W.; Al-Hatamleh, M.A.I.; Hatmal, M.; Smadi, O.; Taha, M.O.; Oweida, A.J.; Boer, J.C.; Mohamud, R.; Plebanski, M. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells, 2020, 9(12), 2638.
[http://dx.doi.org/10.3390/cells9122638] [PMID: 33302501]

Bestle, D.; Heindl, M.R.; Limburg, H.; Van Lam van, T.; Pilgram, O.; Moulton, H.; Stein, D.A.; Hardes, K.; Eickmann, M.; Dolnik, O.; Rohde, C.; Klenk, H.D.; Garten, W.; Steinmetzer, T.; Böttcher-Friebertshäuser, E. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance, 2020, 3(9), e202000786.
[http://dx.doi.org/10.26508/lsa.202000786] [PMID: 32703818]

Xia, S.; Lan, Q.; Su, S.; Wang, X.; Xu, W.; Liu, Z.; Zhu, Y.; Wang, Q.; Lu, L.; Jiang, S. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct. Target. Ther., 2020, 5(1), 92.
[http://dx.doi.org/10.1038/s41392-020-0184-0] [PMID: 32532959]

Costanzo, M.; Caterino, M.; Cevenini, A.; Jung, V.; Chhuon, C.; Lipecka, J.; Fedele, R.; Guerrera, I.C.; Ruoppolo, M. Proteomics reveals that methylmalonyl-CoA mutase modulates cell architecture and increases susceptibility to stress. Int. J. Mol. Sci., 2020, 21(14), 4998.
[http://dx.doi.org/10.3390/ijms21144998] [PMID: 32679819]

Caterino, M.; Ruoppolo, M.; Mandola, A.; Costanzo, M.; Orrù, S.; Imperlini, E. Protein-protein interaction networks as a new perspective to evaluate distinct functional roles of voltage-dependent anion channel isoforms. Mol. Biosyst., 2017, 13(12), 2466-2476.
[http://dx.doi.org/10.1039/C7MB00434F] [PMID: 29028058]

De Pasquale, V.; Costanzo, M.; Siciliano, R.A.; Mazzeo, M.F.; Pistorio, V.; Bianchi, L.; Marchese, E.; Ruoppolo, M.; Pavone, L.M.; Caterino, M. Proteomic analysis of mucopolysaccharidosis IIIB mouse brain. Biomolecules, 2020, 10(3), 355.
[http://dx.doi.org/10.3390/biom10030355] [PMID: 32111039]

Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Hüttenhain, R.; Kaake, R.M.; Richards, A.L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B.J.; Braberg, H.; Fabius, J.M.; Eckhardt, M.; Soucheray, M.; Bennett, M.J.; Cakir, M.; McGregor, M.J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno, E.; Naing, Z.Z.C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; Kirby, I.T.; Melnyk, J.E.; Chorba, J.S.; Lou, K.; Dai, S.A.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C.J.P.; Perica, T.; Pilla, K.B.; Ganesan, S.J.; Saltzberg, D.J.; Rakesh, R.; Liu, X.; Rosenthal, S.B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X-P.; Liu, Y.; Wankowicz, S.A.; Bohn, M.; Safari, M.; Ugur, F.S.; Koh, C.; Savar, N.S.; Tran, Q.D.; Shengjuler, D.; Fletcher, S.J.; O’Neal, M.C.; Cai, Y.; Chang, J.C.J.; Broadhurst, D.J.; Klippsten, S.; Sharp, P.P.; Wenzell, N.A.; Kuzuoglu-Ozturk, D.; Wang, H-Y.; Trenker, R.; Young, J.M.; Cavero, D.A.; Hiatt, J.; Roth, T.L.; Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R.M.; Frankel, A.D.; Rosenberg, O.S.; Verba, K.A.; Agard, D.A.; Ott, M.; Emerman, M.; Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.; d’Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H.S.; Fujimori, D.G.; Ideker, T.; Craik, C.S.; Floor, S.N.; Fraser, J.S.; Gross, J.D.; Sali, A.; Roth, B.L.; Ruggero, D.; Taunton, J.; Kortemme, T.; Beltrao, P.; Vignuzzi, M.; García-Sastre, A.; Shokat, K.M.; Shoichet, B.K.; Krogan, N.J. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583(7816), 459-468.
[http://dx.doi.org/10.1038/s41586-020-2286-9] [PMID: 32353859]

Bolles, M.; Deming, D.; Long, K.; Agnihothram, S.; Whitmore, A.; Ferris, M.; Funkhouser, W.; Gralinski, L.; Totura, A.; Heise, M.; Baric, R.S. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol., 2011, 85(23), 12201-12215.
[http://dx.doi.org/10.1128/JVI.06048-11] [PMID: 21937658]

Awadasseid, A.; Wu, Y.; Tanaka, Y.; Zhang, W. Current advances in the development of SARS-CoV-2 vaccines. Int. J. Biol. Sci., 2021, 17(1), 8-19.
[http://dx.doi.org/10.7150/ijbs.52569] [PMID: 33390829]

Li, Y-D.; Chi, W-Y.; Su, J-H.; Ferrall, L.; Hung, C-F.; Wu, T-C. Coronavirus vaccine development: from SARS and MERS to COVID-19. J. Biomed. Sci., 2020, 27(1), 104.
[http://dx.doi.org/10.1186/s12929-020-00695-2] [PMID: 33341119]

van Doremalen, N.; Haddock, E.; Feldmann, F.; Meade-White, K.; Bushmaker, T.; Fischer, R.J.; Okumura, A.; Hanley, P.W.; Saturday, G.; Edwards, N.J.; Clark, M.H.A.; Lambe, T.; Gilbert, S.C.; Munster, V.J. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci. Adv., 2020, 6(24), eaba8399.
[http://dx.doi.org/10.1126/sciadv.aba8399] [PMID: 32577525]

Alharbi, N.K.; Qasim, I.; Almasoud, A.; Aljami, H.A.; Alenazi, M.W.; Alhafufi, A.; Aldibasi, O.S.; Hashem, A.M.; Kasem, S.; Albrahim, R.; Aldubaib, M.; Almansour, A.; Temperton, N.J.; Kupke, A.; Becker, S.; Abu-Obaidah, A.; Alkarar, A.; Yoon, I.K.; Azhar, E.; Lambe, T.; Bayoumi, F.; Aldowerij, A.; Ibrahim, O.H.; Gilbert, S.C.; Balkhy, H.H. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci. Rep., 2019, 9(1), 16292.
[http://dx.doi.org/10.1038/s41598-019-52730-4] [PMID: 31705137]

Ashfaq, U.A.; Saleem, S.; Masoud, M.S.; Ahmad, M.; Nahid, N.; Bhatti, R.; Almatroudi, A.; Khurshid, M. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach. PLoS One, 2021, 16(2), e0245072.
[http://dx.doi.org/10.1371/journal.pone.0245072] [PMID: 33534822]

Parker, E.P.K.; Shrotri, M.; Kampmann, B. Keeping track of the SARS-CoV-2 vaccine pipeline. Nat. Rev. Immunol., 2020, 20(11), 650-650.
[http://dx.doi.org/10.1038/s41577-020-00455-1] [PMID: 32989290]

Le, T.T.; Cramer, J.P.; Chen, R.; Mayhew, S. Evolution of the COVID-19 vaccine development landscape. Nat. Rev. Drug Discov., 2020, 19(10), 667-668.
[http://dx.doi.org/10.1038/d41573-020-00151-8] [PMID: 32887942]

Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med., 2020, 382(21), 1969-1973.
[http://dx.doi.org/10.1056/NEJMp2005630] [PMID: 32227757]

Strizova, Z.; Smetanova, J.; Bartunkova, J.; Milota, T. Principles and challenges in anti-COVID-19 vaccine development. Int. Arch. Allergy Immunol., 2021, 182(4), 339-349.
[http://dx.doi.org/10.1159/000514225] [PMID: 33524979]

Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; Bailey, R.; Swanson, K.A.; Roychoudhury, S.; Koury, K.; Li, P.; Kalina, W.V.; Cooper, D.; Frenck, R.W., Jr; Hammitt, L.L.; Türeci, Ö.; Nell, H.; Schaefer, A.; Ünal, S.; Tresnan, D.B.; Mather, S.; Dormitzer, P.R.; Şahin, U.; Jansen, K.U.; Gruber, W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med., 2020, 383(27), 2603-2615.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]

Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med., 2021, 384(5), 403-416.
[PMID: 33378609]

Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; Bibi, S.; Briner, C.; Cicconi, P.; Collins, A.M.; Colin-Jones, R.; Cutland, C.L.; Darton, T.C.; Dheda, K.; Duncan, C.J.A.; Emary, K.R.W.; Ewer, K.J.; Fairlie, L.; Faust, S.N.; Feng, S.; Ferreira, D.M.; Finn, A.; Goodman, A.L.; Green, C.M.; Green, C.A.; Heath, P.T.; Hill, C.; Hill, H.; Hirsch, I.; Hodgson, S.H.C.; Izu, A.; Jackson, S.; Jenkin, D.; Joe, C.C.D.; Kerridge, S.; Koen, A.; Kwatra, G.; Lazarus, R.; Lawrie, A.M.; Lelliott, A.; Libri, V.; Lillie, P.J.; Mallory, R.; Mendes, A.V.A.; Milan, E.P.; Minassian, A.M.; McGregor, A.; Morrison, H.; Mujadidi, Y.F.; Nana, A.; O’Reilly, P.J.; Padayachee, S.D.; Pittella, A.; Plested, E.; Pollock, K.M.; Ramasamy, M.N.; Rhead, S.; Schwarzbold, A.V.; Singh, N.; Smith, A.; Song, R.; Snape, M.D.; Sprinz, E.; Sutherland, R.K.; Tarrant, R.; Thomson, E.C.; Torok, M.E.; Toshner, M.; Turner, D.P.J.; Vekemans, J.; Villafana, T.L.; Watson, M.E.E.; Williams, C.J.; Douglas, A.D.; Hill, A.V.S.; Lambe, T.; Gilbert, S.C.; Pollard, A.J. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 2021, 397(10269), 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]

Logunov, D.Y.; Dolzhikova, I.V.; Zubkova, O.V.; Tukhvatulin, A.I.; Shcheblyakov, D.V.; Dzharullaeva, A.S.; Grousova, D.M.; Erokhova, A.S.; Kovyrshina, A.V.; Botikov, A.G.; Izhaeva, F.M.; Popova, O.; Ozharovskaya, T.A.; Esmagambetov, I.B.; Favorskaya, I.A.; Zrelkin, D.I.; Voronina, D.V.; Shcherbinin, D.N.; Semikhin, A.S.; Simakova, Y.V.; Tokarskaya, E.A.; Lubenets, N.L.; Egorova, D.A.; Shmarov, M.M.; Nikitenko, N.A.; Morozova, L.F.; Smolyarchuk, E.A.; Kryukov, E.V.; Babira, V.F.; Borisevich, S.V.; Naroditsky, B.S.; Gintsburg, A.L. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet, 2020, 396(10255), 887-897.
[http://dx.doi.org/10.1016/S0140-6736(20)31866-3] [PMID: 32896291]

Kauffman, K.J.; Webber, M.J.; Anderson, D.G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release, 2016, 240, 227-234.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.032] [PMID: 26718856]

Cimolai, N. Do RNA vaccines obviate the need for genotoxicity studies? Mutagenesis, 2020, 35(6), 509-510.
[PMID: 33216145]

Meurens, F. Multidisciplinary Digital Publishing Institute, 2020.

Sahin, U.; Karikó, K.; Türeci, Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov., 2014, 13(10), 759-780.
[http://dx.doi.org/10.1038/nrd4278] [PMID: 25233993]

Imoukhuede, E.; Payne, R.; Fehling, S.; Strecker, T.; Biedenkopf, N.; Krähling, V.; Tully, C.; Edwards, N.; Bentley, E.; Samuel, D. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA., 2016.

Morris, S.J.; Sebastian, S.; Spencer, A.J.; Gilbert, S.C. Simian adenoviruses as vaccine vectors. Future Virol., 2016, 11(9), 649-659.
[http://dx.doi.org/10.2217/fvl-2016-0070] [PMID: 29527232]

Zhu, F-C.; Li, Y-H.; Guan, X-H.; Hou, L-H.; Wang, W-J.; Li, J-X.; Wu, S-P.; Wang, B-S.; Wang, Z.; Wang, L.; Jia, S.Y.; Jiang, H.D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.B.; Xu, S.B.; Xu, J.J.; Wang, X.W.; Wang, W.; Chen, W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet, 2020, 395(10240), 1845-1854.
[http://dx.doi.org/10.1016/S0140-6736(20)31208-3] [PMID: 32450106]

Sadoff, J.; Le Gars, M.; Shukarev, G.; Heerwegh, D.; Truyers, C.; de Groot, A.M.; Stoop, J.; Tete, S.; Van Damme, W.; Leroux-Roels, I.; Berghmans, P-J.; Kimmel, M.; Van Damme, P.; de Hoon, J.; Smith, W.; Stephenson, K.E.; De Rosa, S.C.; Cohen, K.W.; McElrath, M.J.; Cormier, E.; Scheper, G.; Barouch, D.H.; Hendriks, J.; Struyf, F.; Douoguih, M.; Van Hoof, J.; Schuitemaker, H. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N. Engl. J. Med., 2021.
[http://dx.doi.org/10.1056/NEJMoa2034201] [PMID: 33440088]

Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis., 2021, 21(2), 181-192.
[http://dx.doi.org/10.1016/S1473-3099(20)30843-4] [PMID: 33217362]

Xia, S.; Duan, K.; Zhang, Y.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; Peng, C.; Zhang, Y.; Zhang, W.; Yang, Y.; Chen, W.; Gao, X.; You, W.; Wang, X.; Wang, Z.; Shi, Z.; Wang, Y.; Yang, X.; Zhang, L.; Huang, L.; Wang, Q.; Lu, J.; Yang, Y.; Guo, J.; Zhou, W.; Wan, X.; Wu, C.; Wang, W.; Huang, S.; Du, J.; Meng, Z.; Pan, A.; Yuan, Z.; Shen, S.; Guo, W.; Yang, X. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA, 2020, 324(10), 951-960.
[http://dx.doi.org/10.1001/jama.2020.15543] [PMID: 32789505]

Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis., 2021, 21(1), 39-51.
[http://dx.doi.org/10.1016/S1473-3099(20)30831-8] [PMID: 33069281]

Yang, S.; Li, Y.; Dai, L.; Wang, J.; He, P.; Li, C.; Fang, X.; Wang, C.; Zhao, X.; Huang, E.; Wu, C.; Zhong, Z.; Wang, F.; Duan, X.; Tian, S.; Wu, L.; Liu, Y.; Luo, Y.; Chen, Z.; Li, F.; Li, J.; Yu, X.; Ren, H.; Liu, L.; Meng, S.; Yan, J.; Hu, Z.; Gao, L.; Gao, G.F. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis., 2021.21(8), 1107-1119..
[PMID: 33773111]

Ella, R.; Reddy, S.; Jogdand, H.; Sarangi, V.; Ganneru, B.; Prasad, S.; Das, D.; Raju, D.; Praturi, U.; Sapkal, G.; Yadav, P.; Reddy, P.; Verma, S.; Singh, C.; Redkar, S.V.; Gillurkar, C.S.; Kushwaha, J.S.; Mohapatra, S.; Bhate, A.; Rai, S.; Panda, S.; Abraham, P.; Gupta, N.; Ella, K.; Bhargava, B.; Vadrevu, K.M. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect. Dis., 2021.21(7),950-961..
[PMID: 33705727]

Kochhar, S.; Excler, J-L.; Kim, D.; Robertson, J.S.; Fast, P.E.; Condit, R.C.; Drew, S.; Wood, D.; Gurwith, M.; Klug, B.; Whelan, M.; Khuri-Bulos, N.; Mallett Moore, T.; Smith, E.R.; Chen, R.T. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines. Vaccine, 2020, 38(39), 6184-6189.
[http://dx.doi.org/10.1016/j.vaccine.2020.07.028] [PMID: 32747214]

Tseng, C-T.; Sbrana, E.; Iwata-Yoshikawa, N.; Newman, P.C.; Garron, T.; Atmar, R.L.; Peters, C.J.; Couch, R.B. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One, 2012, 7(4), e35421.
[http://dx.doi.org/10.1371/journal.pone.0035421] [PMID: 22536382]

Jaras, M.; Edqvist, A.; Rebetz, J.; Salford, L.G.; Widegren, B.; Fan, X. Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression. Blood, 2006, 108(3), 1084-1091.
[http://dx.doi.org/10.1182/blood-2005-09-008904] [PMID: 16861355]

Su, Y.; Ghodke, P.P.; Egli, M.; Li, L.; Wang, Y.; Guengerich, F.P. Human DNA polymerase ā has reverse transcriptase activity in cellular environments. J. Biol. Chem., 2019, 294(15), 6073-6081.
[http://dx.doi.org/10.1074/jbc.RA119.007925] [PMID: 30842261]

Shimizu, A.; Nakatani, Y.; Nakamura, T.; Jinno-Oue, A.; Ishikawa, O.; Boeke, J.D.; Takeuchi, Y.; Hoshino, H. Characterisation of cytoplasmic DNA complementary to non-retroviral RNA viruses in human cells. Sci. Rep., 2014, 4, 5074.
[http://dx.doi.org/10.1038/srep05074] [PMID: 24875540]

Schwertz, H.; Rowley, J.W.; Schumann, G.G.; Thorack, U.; Campbell, R.A.; Manne, B.K.; Zimmerman, G.A.; Weyrich, A.S.; Rondina, M.T. Endogenous LINE-1 (long interspersed nuclear element-1) reverse transcriptase activity in platelets controls translational events through RNA.DNA hybrids. Arterioscler. Thromb. Vasc. Biol., 2018, 38(4), 801-815.
[http://dx.doi.org/10.1161/ATVBAHA.117.310552] [PMID: 29301786]

Modjarrad, K. MERS-CoV vaccine candidates in development: The current landscape. Vaccine, 2016, 34(26), 2982-2987.
[http://dx.doi.org/10.1016/j.vaccine.2016.03.104] [PMID: 27083424]

Wang, L.; Shi, W.; Joyce, M.G.; Modjarrad, K.; Zhang, Y.; Leung, K.; Lees, C.R.; Zhou, T.; Yassine, H.M.; Kanekiyo, M.; Yang, Z.Y.; Chen, X.; Becker, M.M.; Freeman, M.; Vogel, L.; Johnson, J.C.; Olinger, G.; Todd, J.P.; Bagci, U.; Solomon, J.; Mollura, D.J.; Hensley, L.; Jahrling, P.; Denison, M.R.; Rao, S.S.; Subbarao, K.; Kwong, P.D.; Mascola, J.R.; Kong, W.P.; Graham, B.S. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun., 2015, 6(1), 7712.
[http://dx.doi.org/10.1038/ncomms8712] [PMID: 26218507]

Sui, J.; Deming, M.; Rockx, B.; Liddington, R.C.; Zhu, Q.K.; Baric, R.S.; Marasco, W.A. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J. Virol., 2014, 88(23), 13769-13780.
[http://dx.doi.org/10.1128/JVI.02232-14] [PMID: 25231316]

Greaney, A.J.; Loes, A.N.; Crawford, K.H.; Starr, T.N.; Malone, K.D.; Chu, H.Y.; Bloom, J.D. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. bio. Rxiv., 2021, 9(3), 463-476.e6.
[http://dx.doi.org/10.1016/j.chom.2021.02.003] [PMID: 33592168]